All In Biotech

Drug Trial Radar · NCT05995964

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-07275315 AND PF-07264660 IN ADULT PARTICIPANTS WITH MODERATE-SEVERE ATOPIC DERMATITIS

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 507 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

507

Actual

Start

Aug 22, 2023

Primary completion

Nov 12, 2026

Study completion Apr 1, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. * Were confirmed to have AD at least 6 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. In Stage 1 of the study, participants will receive either PF-07275315 or PF-07264660 or placebo. Stage 1 is complete. In Stage 2 of the study participants will receive either PF-07275315 or placebo. In Stage 3 of the study participants who have received anti-inflammatory proteins, will receive either PF-07275315 or placebo. In Stage 4 of the study participants will receive either PF-07264660 or placebo. A placebo does not have any medicine in it but looks just like the medicines being studied. PF-07275315 or PF-07264660 or placebo will be given as multiple shots in the clinic over the course of each Stage. The experiences of people receiving PF-07275315 or PF-07264660 will be compared to people who do not. This will help determine if PF-07275315 and PF-07264660 are safe and effective. Participants in Stages 1, 2 and 4 will be involved in this study for up to 40 weeks (10 months). Participants in Stage 3 will be involved in this study for up to 52 weeks (13 months).

Conditions

  • Atopic Dermatitis

Interventions

  • PF-07275315Drug

    subcutaneous injection

  • PF-07264660Drug

    subcutaneous injection

  • PlaceboOther

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.Time frame: Week 16

Locations

96 sites in 7 countries. Site status is shown where the registry gives one.

  • Allervie Clinical Research

    Birmingham, Alabama

  • Onyx Clinical Research - Peoria

    Peoria, Arizona

  • Onyx Clinical Research

    Phoenix, Arizona

  • Banner - University Medicine Dermatology Clinic

    Tucson, Arizona

  • Marvel Clinical Research

    Huntington Beach, California

  • California Allergy and Asthma Medical Group

    Los Angeles, California

  • University Dermatology Trials, INC.

    Newport Beach, California

  • Northridge Clinical Trials

    Northridge, California

  • Profound Research LLC

    Oceanside, California

  • Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.

    San Diego, California

  • West Dermatology La Jolla

    San Diego, California

  • Sunwise Clinical Research

    Walnut Creek, California

  • AboutSkin Research, LLC

    Greenwood Village, Colorado

  • Renaissance Research and Medical Group

    Cape Coral, Florida

  • Florida International Medical Research

    Coral Gables, Florida

  • Revival Research

    Doral, Florida

  • St. Jude Clinical Research

    Doral, Florida

  • SouthCoast Research Center

    Miami, Florida

  • Floridian Research Institute Llc

    Miami, Florida

  • Global Health Research Center, Inc.

    Miami Lakes, Florida

  • Ziaderm Research LLC

    North Miami Beach, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • GCP Research, Global Clinical professionals

    St. Petersburg, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Southern Indiana Clinical Trials

    New Albany, Indiana

  • Maryland Laser Skin and Vein

    Hunt Valley, Maryland

  • Michigan Center for Research Company

    Clarkston, Michigan

  • MI Skin Innovations

    Northville, Michigan

  • Revival Research Institute LLC

    Troy, Michigan

  • Skin Specialists, PC dba Schlessinger MD

    Omaha, Nebraska

  • Empire Dermatology

    East Syracuse, New York

  • Private Practice - Dr. Bobby Buka

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Sadick Research Group

    New York, New York

  • Apex Clinical Research Center

    Mayfield Heights, Ohio

  • Epic Medical Research - Oklahoma

    Chickasha, Oklahoma

  • Unity Clinical Research

    Oklahoma City, Oklahoma

  • Vital Prospects Clinical Research Institute, PC

    Tulsa, Oklahoma

  • Velocity Clinical Research, Medford

    Medford, Oregon

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.